Bone Marrow Transplants for Leukaemia: Complete Guide to Treatment, Recovery & Cost in India

By: Dr. Anand Kumar K
Consultant in Haematology, Bone Marrow Transplant
Posted on August 10, 2024

Leukaemia, a formidable challenge faced by many, demands innovative and effective treatments. Among these, a Bone Marrow Transplant (BMT) for leukaemia stands out as a crucial option, potentially offering hope and a new lease on life for patients battling this relentless disease. Understanding leukaemia and bone marrow transplant, including the role of stem cells and the type of bone marrow transplant for leukaemia, is vital for patients and caregivers alike. Doctors meticulously examine every aspect of the BMT leukaemia treatment, from the stringent selection criteria to the final stages of recovery.

This comprehensive blog illuminates the significance of BMT for leukaemia treatment as a pivotal strategy in the fight against leukaemia, delineating the step-by-step process that characterises this complex treatment option.

What Is a Bone Marrow Transplant?
What Is Leukaemia?
Types of Leukaemia Treated with BMT
When Is BMT Recommended?
Who Qualifies for BMT?
Types of Bone Marrow Transplants
Understanding Donor Matching
Step-by-Step BMT Process
Treatment Timeline
Side Effects and Risks
Recovery Timeline
Success Rates
BMT vs Other Treatments
BMT Cost in India
Why International Patients Choose India

What Is a Bone Marrow Transplant (BMT)?

A bone marrow transplant (BMT), or stem cell transplant, is a medical procedure that involves infusing healthy blood-forming stem cells into the patient’s body to replace compromised bone marrow that is not producing enough healthy blood cells. These transplanted stem cells find their way to the marrow, where they begin producing new, healthy blood cells.

BMT is a specialised therapy for patients with certain cancers or other diseases. It involves taking healthy stem cells, typically found in the bone marrow, filtering them, and infusing them into the patient’s body.

What Is Leukaemia?

Leukaemia is a group of blood cancers that originate in the bone marrow, causing the uncontrolled production of abnormal white blood cells. These abnormal cells crowd out healthy blood cells, leading to anaemia, infection susceptibility, and bleeding disorders. Understanding the specific type of leukaemia is critical for determining whether a bone marrow transplant is the right treatment approach.

Types of Leukaemia Treated with BMT

BMT has been successfully used to treat various diseases, including leukaemia, lymphomas, aplastic anaemia, immune deficiency disorders, and some solid tumour cancers. Specifically, BMT can benefit people with acute leukaemia, chronic leukaemia, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and multiple myeloma.

Leukaemia Type	Onset	Affected Cells	Typical Age Group	BMT Role
Acute Myeloid Leukaemia (AML)	Rapid	Myeloid cells	Adults (median age 68); also children	Primary curative option in high-risk/relapsed disease
Acute Lymphoblastic Leukaemia (ALL)	Rapid	Lymphoid cells	Children (peak 2–5 years); also adults	Curative for high-risk or relapsed ALL
Chronic Myeloid Leukaemia (CML)	Gradual	Myeloid cells	Adults (median age 55–60)	Reserved for TKI-resistant or accelerated/blast phase
Chronic Lymphocytic Leukaemia (CLL)	Gradual	Lymphoid cells	Older adults (median age 70+)	Rarely; considered for young, high-risk patients

Why BMT is Effective

The goal of a BMT is to cure many blood diseases and cancers. In situations where chemotherapy or radiation therapy will permanently damage or destroy a person’s bone marrow stem cells in order to cure cancer, doctors may advise a stem cell transplant. By replacing unhealthy, immature blood cells with healthy ones, BMT can control or cure the disease, extend life, and improve the patient’s quality of life.

When Does Leukaemia Require a Bone Marrow Transplant?

Not every leukaemia patient needs a Bone Marrow Transplant. The decision depends on the type and stage of leukaemia, the patient’s age and overall fitness, response to initial chemotherapy, genetic and molecular risk factors, and the availability of a suitable donor.

AML: When Is BMT Recommended?

First Complete Remission (CR1): Patients with intermediate-risk or high-risk AML (based on cytogenetic and molecular markers such as FLT3-ITD, TP53 mutations, or complex karyotype) are often recommended for allogeneic BMT in CR1 to prevent relapse.

Relapsed or Refractory AML: Patients who relapse after initial chemotherapy or do not achieve remission (refractory disease) are strong candidates for BMT, as it offers the best chance of long-term survival.

Secondary AML: Leukaemia arising from prior myelodysplastic syndrome (MDS) or previous chemotherapy/radiation therapy typically carries a poorer prognosis, making BMT essential for curative intent.

ALL: When Is BMT Recommended?

High-Risk ALL in CR1: Patients with Philadelphia chromosome-positive (Ph+) ALL, MLL rearrangements, hypodiploidy, or persistent minimal residual disease (MRD) after induction therapy.

Relapsed ALL: Any patient with relapsed ALL who achieves a second remission is generally recommended for allogeneic BMT, as chemotherapy alone rarely provides long-term cure in relapsed disease.

Paediatric ALL: While most children are cured with chemotherapy alone, those with very high-risk features or early relapse require BMT.

CML: When Is BMT Recommended?

With the advent of tyrosine kinase inhibitors (TKIs) like imatinib, dasatinib, and nilotinib, BMT is no longer the first-line treatment for CML. However, it remains a curative option for patients who fail multiple TKIs, progress to accelerated or blast phase, or have T315I mutation (resistant to most TKIs except ponatinib).

Who Qualifies for a Bone Marrow Transplant for Leukaemia?

Your oncology and haematology team will evaluate multiple factors before determining suitability for BMT.

General Eligibility Criteria

Cancer Type and Stage: Confirmed diagnosis of leukaemia requiring transplant as per risk stratification and treatment guidelines.
Treatment History: Typically, patients must have achieved remission after initial chemotherapy or be in a state where BMT offers the best curative option.
Age and Fitness: While there is no strict age cut-off, patients must have adequate organ function (cardiac, hepatic, renal, pulmonary). The HCT-CI (Haematopoietic Cell Transplant Comorbidity Index) is used to assess fitness.
Performance Status: ECOG performance status of 0–2 (able to carry out daily activities with minimal or moderate limitations).
Donor Availability: A matched sibling donor, matched unrelated donor, haploidentical donor, or cord blood unit must be identified.
Disease Status: Patients in complete remission (CR1 or CR2) generally have significantly better transplant outcomes than those with active disease.

Who May Not Be Eligible

Patients with severe, uncontrolled infections.
Those with significant organ dysfunction (e.g., ejection fraction <40%, severe pulmonary disease, liver failure).
Patients who are unable to tolerate conditioning chemotherapy.
Elderly patients with high comorbidity scores (HCT-CI ≥4) may be considered for reduced-intensity conditioning (RIC) or may not be eligible.

Types of Bone Marrow Transplant for Leukaemia

The type of transplant recommended depends on the leukaemia subtype, disease risk, patient fitness, and donor availability.

Factor	Autologous BMT	Allogeneic (Matched Sibling)	Allogeneic (Matched Unrelated)	Haploidentical BMT	Cord Blood Transplant
Donor Source	Patient’s own stem cells	HLA-identical sibling	HLA-matched volunteer donor from registry	Half-matched family member (parent, child, sibling)	Stored umbilical cord blood
Donor Availability	Always available	~25–30% chance of sibling match	Depends on ethnicity/registry size	Nearly all patients have a haploidentical donor	Available from cord blood banks
GvHD Risk	None	Moderate (30–50%)	Higher (40–60%)	Moderate with post-transplant cyclophosphamide	Lower (immature immune cells)
Graft-vs-Leukaemia Effect	Minimal	Strong	Strong	Strong	Moderate
Relapse Risk	Higher	Lower	Lower	Lower	Lower
Best For (Leukaemia)	Rarely used for leukaemia; mainly lymphoma/myeloma	First choice when sibling match available	When no sibling match; similar outcomes to matched sibling	When no matched donor available; rapid donor identification	Paediatric patients; when speed of transplant is critical

Understanding Donor Matching for BMT

Finding the right donor is one of the most critical steps in allogeneic bone marrow transplantation. The compatibility between the donor and recipient is determined by Human Leukocyte Antigen (HLA) typing, a set of proteins on the surface of cells that the immune system uses to distinguish self from non-self.

HLA Matching Explained

HLA typing examines a set of genes on chromosome 6. For BMT, doctors typically assess 10 HLA markers (HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 at high resolution). A 10/10 match is considered a fully matched donor. A matched sibling donor (MSD) remains the gold standard, as siblings have a 25% chance of being a perfect HLA match.

When No Matched Donor Is Available

If no matched sibling or unrelated donor can be found, haploidentical transplants using a half-matched family member have become increasingly successful, thanks to advances like post-transplant cyclophosphamide (PTCy) protocols. Cord blood transplants offer another alternative, particularly for paediatric patients, and require less stringent HLA matching (typically 4/6 match is acceptable).

How Bone Marrow Transplant Works: Step-by-Step Process

The bone marrow transplant (BMT) process involves several key steps to ensure the successful replacement of diseased, damaged, or compromised bone marrow with healthy stem cells. Here’s a step-by-step overview:

A. Stem Cell Harvesting:

The surgeon collects stem cells from either the patient (autologous transplant) or a matched donor (allogeneic transplant).
For autologous transplants, stem cells are typically harvested from the patient’s bloodstream or bone marrow before conditioning treatment.
In peripheral blood stem cell harvesting, the patient receives granulocyte colony-stimulating factor (G-CSF) injections to stimulate stem cell production and mobilise them into the bloodstream.
Doctors collect the stem cells through a process called apheresis. During apheresis, they remove the patient’s blood, filter out the stem cells, and return the remaining blood components to the patient.
Alternatively, stem cells can be extracted directly from the bone marrow through a surgical procedure called a bone marrow harvest.
Doctors collect stem cells from the donor’s blood or bone marrow for allogeneic transplants.

B. Conditioning Treatment:

Before the transplant, the patient undergoes conditioning therapy, which involves high-dose chemotherapy or radiation therapy.
The conditioning regimen aims to suppress the patient’s immune system, create space in the bone marrow for the new stem cells, and eliminate any remaining cancer cells.
Cyclophosphamide and busulfan are common chemotherapy drugs used in conditioning, but the specific regimen depends on the patient’s condition and overall health.

C. Transplant Procedure:

Once conditioning is complete, the patient receives the harvested stem cells through an intravenous (IV) infusion, typically through a central venous catheter.
These infused stem cells then travel to the patient’s bone marrow, where they start generating new, healthy blood cells over the next few weeks.

D. Post-Transplant Recovery:

After the transplant, the patient remains in the hospital for several weeks to monitor for complications and allow the new stem cells to engraft (establish themselves in the bone marrow).
During this time, the patient may experience side effects such as fatigue, nausea, and diarrhoea, as well as an increased possibility of infections due to a weakened immune system.
Regular blood transfusions and supportive care, including antibiotics and growth factors, may be necessary until the new bone marrow starts producing sufficient blood cells.
Once the patient is stable or their blood counts recover, they can be discharged from the hospital, but close monitoring and follow-up appointments will continue for an extended period.

It’s important to note that the recovery process can take several months, and the patient’s immune system may remain compromised during this time, requiring precautions to prevent infections, says “Dr. Anand Kumar N.”

Bone Marrow Transplant Treatment Process Timeline

Understanding the full treatment journey helps patients and families prepare. The following timeline outlines each phase:

Phase	Timeline	What Happens	Where
Pre-Transplant Evaluation	Week 1–3	Comprehensive oncology assessment, HLA typing, imaging, bone marrow biopsy, organ function tests, eligibility confirmation	Outpatient clinic
Donor Search & Selection	Week 1–6	HLA typing of family; registry search if no sibling match; donor health screening and workup	Laboratory / Registry coordination
Stem Cell Collection	Week 4–6	PBSC apheresis (5–6 hours), bone marrow harvest, or cord blood retrieval; G-CSF for 4–5 days pre-collection for PBSC	Apheresis centre / Operating room
Conditioning Chemotherapy	Days −7 to −2	Myeloablative, reduced-intensity, or non-myeloablative regimen administered; central line placement	Hospital (inpatient)
Transplant Day (Day 0)	Day 0	Stem cell infusion via IV over 1–4 hours	Hospital BMT unit
Engraftment Period	Day 1–28	Close monitoring for engraftment, infections, GvHD; daily blood work; transfusion support; neutrophil recovery expected Day 14–21	Hospital BMT unit / ICU if needed
Early Recovery	Day 28–100	Outpatient monitoring 2–3 times per week; GvHD assessment; immunosuppressive medication management; remain near hospital	Outpatient clinic / nearby accommodation
Response Assessment	Day 28–100	Bone marrow biopsy, MRD testing, chimerism studies to confirm donor engraftment and leukaemia remission	Outpatient clinic
Long-Term Follow-Up	Month 3 onwards	Gradual tapering of immunosuppression; monitoring for chronic GvHD, relapse, late effects; revaccination programme	Outpatient clinic

Side Effects and Risks of Bone Marrow Transplant for Leukaemia

BMT is a complex procedure with significant risks. Understanding these helps patients and caregivers prepare for the transplant journey.

Short-Term Side Effects (First 100 Days)

Mucositis: Painful inflammation of the mouth and throat lining, making eating and swallowing difficult. Typically resolves within 2–3 weeks after conditioning.
Nausea and Vomiting: Caused by conditioning chemotherapy; managed with anti-emetic medications.
Increased Possibility of Infections: Bacterial, viral (including CMV reactivation), and fungal infections are common during the neutropenic phase. Prophylactic antibiotics, antivirals, and antifungals are standard.
Low Blood Cell Counts: After the conditioning treatment, patients may have low red blood cell levels (anaemia), platelets (increased risk of bleeding), and white blood cells (increased infection risk). Doctors may provide blood transfusions and supportive care during this period.
Diarrhoea: Various treatment modalities during this procedure, including chemotherapy, radiation, infections, or graft-versus-host disease (GvHD), can lead to severe diarrhoea, requiring prompt medical attention and treatment.
Fatigue and Weakness: Patients often feel extremely tired and run down, especially during the second and third weeks when blood cell counts are at their lowest. This fatigue can persist for an extended period after the transplant.

Patients with inherited bleeding disorders may also benefit from understanding conditions such as Haemophilia: Symptoms, Causes and Types and how blood disorders affect treatment planning.

Long-Term Risks (Beyond 100 Days)

Chronic Graft-versus-Host Disease (cGvHD): Can affect skin, eyes, mouth, lungs, joints, and other organs. Occurs in 30–70% of allogeneic transplant survivors and may require long-term immunosuppressive therapy.
Relapse: The leukaemia may return despite transplant, particularly in high-risk disease or when the graft-versus-leukaemia (GvL) effect is insufficient.
Infertility: High-dose conditioning regimens frequently cause permanent infertility. Fertility preservation should be discussed before treatment.
Secondary Cancers: Increased risk of secondary malignancies, particularly skin cancers and myelodysplastic syndromes, years after transplant.
Endocrine Disorders: Thyroid dysfunction, growth hormone deficiency (in paediatric patients), and adrenal insufficiency.
Graft Failure: The transplanted stem cells may fail to engraft or may be rejected, requiring a second transplant or salvage therapy.

Management of Side Effects

While the side effects and risks of BMTs can be significant, medical teams are equipped to manage and mitigate these complications. Preventive measures, prompt treatment, and close monitoring can help alleviate the severity of side effects and improve patient outcomes. Patients must communicate concerns or symptoms with their medical team to receive appropriate care and support throughout the BMT process.

Acute GvHD Severity Grading

Grade	Symptoms	Treatment	Frequency
Grade I (Mild)	Skin rash covering <25% body; no liver or gut involvement	Topical steroids; observation	20–30% of patients
Grade II (Moderate)	Skin rash 25–50% body; mild liver dysfunction (bilirubin 2–3 mg/dL); mild diarrhoea	Systemic corticosteroids (1–2 mg/kg/day)	15–25% of patients
Grade III (Severe)	Generalised skin rash; significant liver dysfunction (bilirubin 3–6 mg/dL); severe diarrhoea (>1 L/day)	High-dose steroids; second-line agents (ruxolitinib, anti-thymocyte globulin)	5–15% of patients
Grade IV (Life-Threatening)	Bullous skin disease; severe liver failure (bilirubin >6 mg/dL); bloody diarrhoea, ileus	Intensive immunosuppression; ICU management; experimental therapies	1–5% of patients

Bone Marrow Transplant Recovery Timeline

Recovery from BMT is a gradual process that varies significantly among individuals. The following outlines general expectations:

Time Period	What to Expect	Key Milestones
Week 1–3	Highest-risk period; hospitalised in BMT unit; profound fatigue, mucositis, fevers, pancytopenia; IV antibiotics and transfusions	Neutrophil engraftment (Day 14–21); first signs of blood count recovery
Week 3–6	Gradual improvement; may transition to outpatient; blood counts rising; risk of acute GvHD onset; remain near hospital	Hospital discharge (typically Day 21–35); platelet engraftment
Month 2–3	Energy slowly improving; infection risk still elevated; frequent clinic visits (2–3/week); immunosuppressive medication management	Day 100 assessment: bone marrow biopsy, chimerism, MRD testing
Month 3–6	Most patients resume light daily activities; ongoing GvHD management; immune reconstitution progressing	Immunosuppression tapering begins; some patients return to work
Month 6–12	Near-normal energy for many; continued monitoring for chronic GvHD and relapse; revaccination programme starts	6- and 12-month response assessments; immune recovery benchmarks
Year 1+	Long-term survivors monitored annually; screening for late effects (secondary cancers, endocrine issues); quality of life improving	Annual check-ups; long-term remission surveillance; complete immune reconstitution in many patients by 1–2 years

How Successful Is Bone Marrow Transplant for Leukaemia?

Success rates vary significantly based on leukaemia type, disease status at transplant, patient age and fitness, donor type, and conditioning regimen. Survival outcomes have improved substantially over the past two decades due to better supportive care, improved donor matching, and advanced GvHD prevention strategies.

Success Rates by Leukaemia Type

Leukaemia Type	Disease Status at Transplant	5-Year Overall Survival	Relapse Rate	Key Prognostic Factors
AML (CR1, intermediate risk)	First complete remission	50–65%	20–35%	Cytogenetics, MRD status, donor match
AML (CR1, high risk)	First complete remission	40–55%	30–45%	FLT3-ITD, TP53, complex karyotype
AML (CR2/relapsed)	Second remission	30–45%	40–55%	Duration of first remission, MRD
ALL (Paediatric, CR1 high risk)	First complete remission	55–70%	15–30%	MRD negativity, Ph+ status
ALL (Adult, CR1)	First complete remission	45–60%	25–40%	Age, cytogenetics, MRD
CML (Accelerated/Blast)	After TKI failure	30–50%	30–50%	Phase at transplant, TKI response history

Paediatric vs Adult Bone Marrow Transplant for Leukaemia

Transplant outcomes and considerations differ significantly between children and adults.

Factor	Paediatric Patients	Adult Patients
Most Common Indication	High-risk or relapsed ALL; high-risk AML	AML (intermediate/high risk in CR1); relapsed ALL
Conditioning Tolerance	Better tolerance of myeloablative conditioning; TBI commonly used	Higher toxicity risk; RIC increasingly used for patients >50 years
GvHD Incidence	Generally lower rates of chronic GvHD	Higher rates of both acute and chronic GvHD
Overall Survival (5-Year)	55–70% for ALL; 50–65% for AML	40–65% for AML in CR1; 45–60% for ALL
Long-Term Considerations	Growth and development monitoring; endocrine follow-up; neurocognitive assessment; fertility preservation planning	Fertility, cardiac and pulmonary late effects; secondary cancers; psychosocial support; return to work planning

BMT vs Other Leukaemia Treatments

BMT vs Chemotherapy Alone

Factor	Bone Marrow Transplant	Chemotherapy Alone
Curative Potential	High for eligible patients; GvL effect provides ongoing anti-leukaemia surveillance	Curative for standard-risk ALL in children; limited for high-risk or relapsed leukaemia
Treatment Duration	6–12 months (acute phase + recovery)	2–3 years for ALL maintenance; 6–12 months for AML
Relapse Risk	Lower for high-risk disease due to GvL effect	Higher for intermediate/high-risk leukaemia
Toxicity Profile	Higher upfront (GvHD, infections, organ toxicity); lower long-term treatment burden	Cumulative toxicity over prolonged treatment; neuropathy, cardiotoxicity, secondary cancers
Best For	High-risk or relapsed leukaemia where chemotherapy alone is insufficient	Standard-risk leukaemia where transplant risks outweigh benefits

BMT vs CAR T-Cell Therapy

Factor	Bone Marrow Transplant	CAR T-Cell Therapy
Mechanism	Replaces entire blood and immune system with donor cells; GvL effect	Patient’s own T-cells genetically engineered to target specific cancer antigens (CD19, BCMA)
Donor Requirement	Requires matched donor (allogeneic)	No donor needed (uses patient’s own cells)
Hospital Stay	3–6 weeks inpatient	7–14 days typically
Major Risks	GvHD (30–50%), graft failure, organ toxicity	Cytokine Release Syndrome (CRS), neurotoxicity (ICANS)
Long-Term Remission	Established long-term data; 40–65% 5-year survival for AML	Emerging long-term data; up to 50–60% 2-year survival for ALL/DLBCL
Current Role in Leukaemia	Standard curative therapy for high-risk and relapsed leukaemia	Primarily for relapsed/refractory B-cell ALL; increasingly used as bridge to or alternative to BMT

Post-Transplant Relapse: What You Should Know

Relapse after BMT remains the leading cause of treatment failure. The risk is highest in the first 1-2 years after transplant and depends on the leukaemia type and risk stratification, disease status at transplant (active disease vs. remission), MRD status before and after transplant, degree of donor chimerism, and presence or absence of GvHD (mild GvHD may actually reduce relapse risk through the GvL effect).

Options After Relapse

Donor Lymphocyte Infusion (DLI): Infusion of additional donor immune cells to boost the GvL effect.
Targeted Therapy: FLT3 inhibitors (gilteritinib), IDH inhibitors, or hypomethylating agents depending on molecular profile.
CAR T-Cell Therapy: Increasingly used for relapsed B-cell ALL after BMT.
Second Transplant: Considered in select patients who achieve second remission.
Immunosuppression Reduction: Rapid tapering of immunosuppression to allow the donor immune system to target residual leukaemia.

Bone Marrow Transplant Cost in India for Leukaemia

Cost is one of the most important considerations for patients and families. India has emerged as a significantly more affordable destination for BMT compared to Western countries, with outcomes comparable to international standards.

What Does the Cost Include?

Pre-transplant evaluation and diagnostic workup (HLA typing, bone marrow biopsy, imaging, organ function tests)
Donor search coordination and workup (if allogeneic)
Stem cell collection (apheresis or bone marrow harvest)
Conditioning chemotherapy and supportive medications
Hospital stay during engraftment (3–6 weeks in BMT unit)
ICU management if complications arise
Blood product transfusions, antimicrobial prophylaxis, and growth factors
Initial post-transplant follow-up (Day 100 assessment)

Additional costs may include unrelated donor procurement fees (from international registries), extended hospital stays for GvHD management, long-term immunosuppressive medications, immunoglobulin replacement, and revaccination.

For a personalised treatment estimate and transplant cost breakdown, from the SPARSH Hospitals – Global Care team.

Why International Patients Choose India for BMT

Cost Savings of 70–90%: BMT in India costs a fraction of what patients pay in the US, UK, or Europe, without compromising quality or outcomes.
NABH-Accredited Hospitals: India’s leading cancer centres meet international quality and safety standards.
Experienced Haematology Teams: Indian BMT specialists are trained at leading global institutions and collectively perform thousands of transplants annually.
Shorter Wait Times: Patients can often begin the treatment process within 1–2 weeks of arriving in India.
Comprehensive International Patient Support: Leading hospitals provide end-to-end services including visa assistance, airport transfers, accommodation, interpreter services, and dedicated patient coordinators.
Established Medical Tourism Infrastructure: Bangalore, Mumbai, Delhi, and Chennai have well-established ecosystems for handling international patients.

When to See a Doctor

Consider consulting a haematologist or BMT specialist about bone marrow transplant for leukaemia in the following situations:

Relapsed or Refractory Leukaemia: If your leukaemia has returned after initial treatment or does not respond to standard chemotherapy.
High-Risk Disease at Diagnosis: If genetic or molecular testing identifies high-risk features that indicate BMT should be part of the treatment plan.
Considering Treatment Options: If you want to understand all available options including BMT, CAR T-cell therapy, and targeted therapies.
Seeking a Second Opinion: A second opinion from a transplant centre can provide valuable perspective on your treatment plan.
International Patients: If you are considering India for affordable, high-quality BMT treatment.

Conclusion

A bone marrow transplant can be a life-saving procedure for those with serious blood disorders. Getting the right medical care is essential for a successful transplant and recovery. The Best Bone Marrow Transplant Hospital in Bangalore offers advanced treatment and expert care. Consulting the Best Bone Marrow Transplant Doctors in Bangalore ensures you receive the best support for a healthier future.